Dose rate modulation for the safe delivery of retreatment irradiation in recurrent glioma patients

H. Ian Robins, Wolfgang A. Tome, Steve P. Howard

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In spite of the continued evolution of surgical and chemotherapeutic approaches tothe treatment of low and high-grade glioma patients, most patients recur, at which timetheir therapeutic options are limited. Most recently the conditional approval ofbevacizumab by the FDA for the recurrent glioblastoma patients has offered a significantimprovement in progression free survival. Efficacy, however, regarding overall survivalhas been limited. One unique approach to such recurrent glioma patients is the use ofdose rate modulated re-treatment irradiation. Radiotherapy (RT) delivered below standarddose-rates reduces normal tissue toxicity and can induce significant tumor regression insome tumor types including glioma. By reducing the effective dose-rate and increasingthe treatment time, it becomes possible for repair processes to be active duringirradiation. This reduction in dose-rate can result in a therapeutic advantage, as repair ofsub-lethal damage in normal neural tissues is greater for late complications than forneoplastic cells; further tumor cells (that have received prior RT) can accumulate in asensitive phase of the cell cycle, e.g., G2, thus leaving them at risk for radiation inducedkilling. In the chapter to follow, modeling for this approach, technological details, well asbiophysical basis for its application is summarized. The published peer reviewed clinical literature on the treatment of recurrent glioma patients using this technique is reviewed in detail: This literature, which encompasses relatively large treatment volumes, is consistent with the concept that fractionated reduced dose-rate external beam RT can achieve an improved therapeutic index. Also outlined are the current planned prospective clinical studies for evaluation this new approach in the context of cooperative group clinical trials in recurrent glioblastoma patients.

Original languageEnglish (US)
Title of host publicationGliomas: Symptoms, Diagnosis and Treatment Options
PublisherNova Science Publishers, Inc.
Pages167-176
Number of pages10
ISBN (Print)9781626180895
StatePublished - May 2013
Externally publishedYes

Fingerprint

Retreatment
Radiotherapy
Glioma
Tumors
Modulation
Irradiation
Repair
Cells
Tissue
Dosimetry
Toxicity
Therapeutics
Glioblastoma
Radiation
Neoplasms
Disease-Free Survival
Cell Cycle
Clinical Trials
Prospective Studies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Ian Robins, H., Tome, W. A., & Howard, S. P. (2013). Dose rate modulation for the safe delivery of retreatment irradiation in recurrent glioma patients. In Gliomas: Symptoms, Diagnosis and Treatment Options (pp. 167-176). Nova Science Publishers, Inc..

Dose rate modulation for the safe delivery of retreatment irradiation in recurrent glioma patients. / Ian Robins, H.; Tome, Wolfgang A.; Howard, Steve P.

Gliomas: Symptoms, Diagnosis and Treatment Options. Nova Science Publishers, Inc., 2013. p. 167-176.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ian Robins, H, Tome, WA & Howard, SP 2013, Dose rate modulation for the safe delivery of retreatment irradiation in recurrent glioma patients. in Gliomas: Symptoms, Diagnosis and Treatment Options. Nova Science Publishers, Inc., pp. 167-176.
Ian Robins H, Tome WA, Howard SP. Dose rate modulation for the safe delivery of retreatment irradiation in recurrent glioma patients. In Gliomas: Symptoms, Diagnosis and Treatment Options. Nova Science Publishers, Inc. 2013. p. 167-176
Ian Robins, H. ; Tome, Wolfgang A. ; Howard, Steve P. / Dose rate modulation for the safe delivery of retreatment irradiation in recurrent glioma patients. Gliomas: Symptoms, Diagnosis and Treatment Options. Nova Science Publishers, Inc., 2013. pp. 167-176
@inbook{dabb454ebd134e0189a98b3ce47c618a,
title = "Dose rate modulation for the safe delivery of retreatment irradiation in recurrent glioma patients",
abstract = "In spite of the continued evolution of surgical and chemotherapeutic approaches tothe treatment of low and high-grade glioma patients, most patients recur, at which timetheir therapeutic options are limited. Most recently the conditional approval ofbevacizumab by the FDA for the recurrent glioblastoma patients has offered a significantimprovement in progression free survival. Efficacy, however, regarding overall survivalhas been limited. One unique approach to such recurrent glioma patients is the use ofdose rate modulated re-treatment irradiation. Radiotherapy (RT) delivered below standarddose-rates reduces normal tissue toxicity and can induce significant tumor regression insome tumor types including glioma. By reducing the effective dose-rate and increasingthe treatment time, it becomes possible for repair processes to be active duringirradiation. This reduction in dose-rate can result in a therapeutic advantage, as repair ofsub-lethal damage in normal neural tissues is greater for late complications than forneoplastic cells; further tumor cells (that have received prior RT) can accumulate in asensitive phase of the cell cycle, e.g., G2, thus leaving them at risk for radiation inducedkilling. In the chapter to follow, modeling for this approach, technological details, well asbiophysical basis for its application is summarized. The published peer reviewed clinical literature on the treatment of recurrent glioma patients using this technique is reviewed in detail: This literature, which encompasses relatively large treatment volumes, is consistent with the concept that fractionated reduced dose-rate external beam RT can achieve an improved therapeutic index. Also outlined are the current planned prospective clinical studies for evaluation this new approach in the context of cooperative group clinical trials in recurrent glioblastoma patients.",
author = "{Ian Robins}, H. and Tome, {Wolfgang A.} and Howard, {Steve P.}",
year = "2013",
month = "5",
language = "English (US)",
isbn = "9781626180895",
pages = "167--176",
booktitle = "Gliomas: Symptoms, Diagnosis and Treatment Options",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Dose rate modulation for the safe delivery of retreatment irradiation in recurrent glioma patients

AU - Ian Robins, H.

AU - Tome, Wolfgang A.

AU - Howard, Steve P.

PY - 2013/5

Y1 - 2013/5

N2 - In spite of the continued evolution of surgical and chemotherapeutic approaches tothe treatment of low and high-grade glioma patients, most patients recur, at which timetheir therapeutic options are limited. Most recently the conditional approval ofbevacizumab by the FDA for the recurrent glioblastoma patients has offered a significantimprovement in progression free survival. Efficacy, however, regarding overall survivalhas been limited. One unique approach to such recurrent glioma patients is the use ofdose rate modulated re-treatment irradiation. Radiotherapy (RT) delivered below standarddose-rates reduces normal tissue toxicity and can induce significant tumor regression insome tumor types including glioma. By reducing the effective dose-rate and increasingthe treatment time, it becomes possible for repair processes to be active duringirradiation. This reduction in dose-rate can result in a therapeutic advantage, as repair ofsub-lethal damage in normal neural tissues is greater for late complications than forneoplastic cells; further tumor cells (that have received prior RT) can accumulate in asensitive phase of the cell cycle, e.g., G2, thus leaving them at risk for radiation inducedkilling. In the chapter to follow, modeling for this approach, technological details, well asbiophysical basis for its application is summarized. The published peer reviewed clinical literature on the treatment of recurrent glioma patients using this technique is reviewed in detail: This literature, which encompasses relatively large treatment volumes, is consistent with the concept that fractionated reduced dose-rate external beam RT can achieve an improved therapeutic index. Also outlined are the current planned prospective clinical studies for evaluation this new approach in the context of cooperative group clinical trials in recurrent glioblastoma patients.

AB - In spite of the continued evolution of surgical and chemotherapeutic approaches tothe treatment of low and high-grade glioma patients, most patients recur, at which timetheir therapeutic options are limited. Most recently the conditional approval ofbevacizumab by the FDA for the recurrent glioblastoma patients has offered a significantimprovement in progression free survival. Efficacy, however, regarding overall survivalhas been limited. One unique approach to such recurrent glioma patients is the use ofdose rate modulated re-treatment irradiation. Radiotherapy (RT) delivered below standarddose-rates reduces normal tissue toxicity and can induce significant tumor regression insome tumor types including glioma. By reducing the effective dose-rate and increasingthe treatment time, it becomes possible for repair processes to be active duringirradiation. This reduction in dose-rate can result in a therapeutic advantage, as repair ofsub-lethal damage in normal neural tissues is greater for late complications than forneoplastic cells; further tumor cells (that have received prior RT) can accumulate in asensitive phase of the cell cycle, e.g., G2, thus leaving them at risk for radiation inducedkilling. In the chapter to follow, modeling for this approach, technological details, well asbiophysical basis for its application is summarized. The published peer reviewed clinical literature on the treatment of recurrent glioma patients using this technique is reviewed in detail: This literature, which encompasses relatively large treatment volumes, is consistent with the concept that fractionated reduced dose-rate external beam RT can achieve an improved therapeutic index. Also outlined are the current planned prospective clinical studies for evaluation this new approach in the context of cooperative group clinical trials in recurrent glioblastoma patients.

UR - http://www.scopus.com/inward/record.url?scp=84892935350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892935350&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892935350

SN - 9781626180895

SP - 167

EP - 176

BT - Gliomas: Symptoms, Diagnosis and Treatment Options

PB - Nova Science Publishers, Inc.

ER -